The American pharmaceutical company Merck is discussing the possible field of biotechnology specializing in the treatment of cancer, Seagen, wrote the Wall Street Journal on Friday.
Turnover of $ 1.6 billion for Sigan in 2021
Seagen was valued at $ 27 billion at the close of trading on Thursday. In the middle of the session on Friday, its share increased by 16%, while the share of Merck, known as MSD outside North America, decreased by 1.5%. The two companies are discussingfor some timeև The agreement does not seem imminent, writes business daily, citing sources familiar with the issue. They are particularly aware of the dangers of being blocked by competitors, and may eventually decide to establish a large-scale trade partnership rather than continue the procurement process. Merck and Siegen, who are already collaborating on research projects, did not immediately respond to AFP’s request. With Seagen, Merck will strengthen its cancer drug portfolio, which is currently dominated by its blockbuster Keytruda.
American biotechnology is developing targeted therapies aimed at more accurately targeting cancer cells, thus reducing side effects. Seagen, which grossed $ 1.6 billion in 2021, is working on treating cancer and hematologic cancer.
Source: Le Figaro
I’m Liza Grey, an experienced news writer and author at the Buna Times. I specialize in writing about economic issues, with a focus on uncovering stories that have a positive impact on society. With over seven years of experience in the news industry, I am highly knowledgeable about current events and the ways in which they affect our daily lives.